About everolimus
mTOR kinase inhibitor
Used for
- Certain advanced kidney, breast, pancreatic, and other cancers
- Subependymal giant cell astrocytoma associated with tuberous sclerosis complex
- Kidney angiomyolipoma associated with tuberous sclerosis complex
Usual adult dose
Cancer: usually 10 mg once daily. Tuberous sclerosis conditions: dose is individualized by indication and sometimes blood levels.
Usual dose in children
For tuberous sclerosis-associated brain tumors or kidney angiomyolipoma: individualized, often starting at 4.5 mg/m² once daily; specialist monitoring is required.
Common side effects
- Mouth sores and inflammation
- Infections
- Rash
- Diarrhea, fatigue, or reduced blood-cell counts
Important warnings
- Can cause serious infections and reduced blood-cell counts.
- May cause lung inflammation, kidney problems, or high blood sugar and cholesterol.
- Avoid live vaccines; vaccination responses may be reduced.
- Regular blood tests and monitoring are important; do not stop or change treatment without the prescriber.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 8 weeks after the final dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 2 weeks after the final dose.
Interactions
- Strong CYP3A4/P-glycoprotein inhibitors, such as clarithromycin, can increase levels.
- Strong CYP3A4/P-glycoprotein inducers, such as rifampin, can reduce levels.
- Grapefruit may increase levels; avoid it.
- Live vaccines may be unsafe or less effective.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.